| Company/Division name | Mallinckrodt Pharmaceuticals |
| Parent company | Mallinckrodt Pharmaceuticals |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Country(ies) from which reshored: | Ireland |
| City reshored to: | Madison |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | StrataGraft regenerative skin tissue |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Customer responsiveness improvement, Eco-system synergies, Other, expansion of current production / facilities |
